JUNS logo

JUNS
Jupiter Neurosciences Inc.

666
Mkt Cap
$8.63M
Volume
8.45M
52W High
$3.33
52W Low
$0.1721
PE Ratio
-0.89
JUNS Fundamentals
Price
$0.2378
Prev Close
$0.2708
Open
$0.2549
50D MA
$0.3685
Beta
0.25
Avg. Volume
93,223.70
EPS (Annual)
-$0.2496
P/B
-3.10
Rev/Employee
$4,359.20
$36.85
Loading...
Loading...
News
all
press releases
Micro-Cap Biotech Stocks Surge After Breakthrough Psychedelics Licensing Announcement
The psychedelics market continues to expand rapidly as researchers gain a deeper understanding of its potential therapeutic benefits. Today, a leader in the sector announced a partnership with another micro-cap biotech company to further advance its development efforts in the space. Investors responded positively to the news, sending shares of both companies sharply higher following the announcement.PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) announced that it has signed a term sheet with Jupiter Neurosciences, Inc. (NASDAQ: JUNS) to grant the company exclusive perpetual U.S. ...
News Placeholder
More News
News Placeholder
Jupiter Stock Soars After $100 Million ALA-002 Licensing Deal
Jupiter Neurosciences shares are rising Wednesday after it announced the acquisition of US licensing rights to ALA-002 from Pharmala Biotech.read more...
News Placeholder
JUNS Stock Sees Best Single-Day Gains In Almost A Year On $100M MDMA Drug Licensing Deal  – Retail Expects Shares To Hit $1
Jupiter Neurosciences signed a term sheet to acquire exclusive U.S. licensing rights to an MDMA-based drug candidate developed by PharmAla Biotech.
News Placeholder
Jupiter Neurosciences Investor News: Rosen Law Firm Encourages Jupiter Neurosciences, Inc. Investors to Inquire About Securities Class Action Investigation JUNS
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Jupiter Neurosciences, Inc. (NASDAQ: JUNS) resulting...
News Placeholder
Rosen Law Firm Encourages Jupiter Neurosciences, Inc. Investors to Inquire About Securities Class Action Investigation JUNS
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Jupiter Neurosciences, Inc. (NASDAQ: JUNS) resulting...
<
...
1
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available